Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Shionogi & Co. Ltd. (OTC: SGIOY).

Full DD Report for SGIOY

You must become a subscriber to view this report.


Recent News from (OTC: SGIOY)

Shionogi & Co. Ltd. ADR 2017 Q4 - Results - Earnings Call Slides
The following slide deck was published by Shionogi & Co. Ltd. ADR in conjunction with their 2017 Q4 earnings Read more ...
Source: SeekingAlpha
Date: May, 10 2018 15:03
European advisory group backs ViiV Healthcare's two-drug HIV pill Juluca
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopts a positive opinion recommending approval for ViiV Healthcare's Juluca (dolutegravir/rilpivirine) for the treatment of HIV-1-infected adults who are virologically suppressed (HIV-1 RNA <50 copies...
Source: SeekingAlpha
Date: March, 23 2018 07:48
Shionogi & Co (SGIOY) Updates On Research And Development - Slideshow
The following slide deck was published by Shionogi & Co. Ltd. ADR in conjunction with this Read more ...
Source: SeekingAlpha
Date: March, 15 2018 13:47
Gilead's HIV med Biktarvy on par with Viiv's Triumeq in late-stage study
Results from a Phase 3 clinical trial, Study 1844, demonstrated the non-inferiority of Gilead Sciences' ( GILD -1% ) Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg) to ViiV Healthcare's Triumeq (abacavir 600 mg/dolutegravir 50 mg/lamivudine 300 mg) in vir...
Source: SeekingAlpha
Date: March, 05 2018 14:21
Japan OK's Shionogi drug that can kill flu virus in 24 hours
The WSJ reports  that the Japanese Ministry of Health, Labor and Welfare has approved Shionogi's ( OTCPK:SGIOF )( OTCPK:SGIOY ) Xofluza, which can apparently kill the flu virus in 24 hours with a single oral dose, handily beating Roche's ( OTCQX:RHHBY ) top-selling Tamiflu (oseltami...
Source: SeekingAlpha
Date: February, 23 2018 08:03
FDA tentatively OKs Mylan's HIV combo pill
The FDA has tentatively approved Mylan N.V.'s ( MYL -1.4% ) fixed-dose combination of dolutegravir, emtricitabine and tenofovir alafenamide for the treatment of HIV infection in developing countries. More news on: Mylan Inc, Gilead Sciences, Inc., GlaxoSmithKline, Healthcare stocks new...
Source: SeekingAlpha
Date: February, 20 2018 11:38
ViiV Healthcare sues Gilead for patent infringement over bictegravir
ViiV Healthcare has filed a patent infringement lawsuit against Gilead Sciences (NASDAQ: GILD ) claiming bictegravir, a component of Gilead's just-approved triple combo HIV pill, infringes on ViiV's dolutegravir and other compounds. More news on: Gilead Sciences, Inc., GlaxoSmithKline, P...
Source: SeekingAlpha
Date: February, 08 2018 06:16
Shionogi & Co. Ltd. ADR 2017 Q3 - Results - Earnings Call Slides
The following slide deck was published by Shionogi & Co. Ltd. ADR in conjunction with their 2017 Q3 earnings Read more ...
Source: SeekingAlpha
Date: February, 05 2018 14:08
ViiV Healthcare launches late-stage study assessing long-acting two-drug combo for HIV-1
ViiV Healthcare, the HIV-focused venture jointly owned by GlaxoSmithKline ( GSK +2.1% ), Pfizer ( PFE +0.1% ) and Shionogi ( OTCPK:SGIOF )( OTCPK:SGIOY ), commences a Phase 3 clinical trial assessing the combination of cabotegravir and rilpivirine for the treatment of virally suppresse...
Source: SeekingAlpha
Date: November, 27 2017 10:17
Shionogi & Co. Ltd. ADR 2018 Q2 - Results - Earnings Call Slides
The following slide deck was published by Shionogi & Co. Ltd. ADR in conjunction with their 2018 Q2 earnings Read more ...
Source: SeekingAlpha
Date: October, 31 2017 14:18

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-14109.08108.75109.08107.124,900
2018-08-13112.76112.76112.76112.76561
2018-08-10N/A112.09N/AN/A92
2018-08-09N/A112.09N/AN/A12
2018-08-08N/A112.09N/AN/A75

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-152,6004,38859.2525Short
2018-08-031,5004,13936.2406Short
2018-08-022220110.9453Cover
2018-07-311003,3482.9869Cover
2018-07-175182,15824.0037Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on SGIOY.


About Shionogi & Co. Ltd. (OTC: SGIOY)

Logo for Shionogi & Co. Ltd. (OTC: SGIOY)

Not available

 

Contact Information

 

 

Current Management

  • Isao Teshirogi Ph.D. / President
  • Motozo Shiono / Chairman

Current Share Structure

  • Market Cap: $18,434,648,663 - 03/09/2018
  • Issue and Outstanding: 351,136,165 - 03/31/2012

 


Recent Filings from (OTC: SGIOY)

Filing to become effective immediately upon filing
Filing Type: F-6EFFiling Source: edgar
Filing Date: April, 25 2016

 

 


Daily Technical Chart for (OTC: SGIOY)

Daily Technical Chart for (OTC: SGIOY)


Stay tuned for daily updates and more on (OTC: SGIOY)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: SGIOY)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in SGIOY is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of SGIOY and does not buy, sell, or trade any shares of SGIOY. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/